The TOMMORROW secondary AD prevention trial (NCT01931566) tested whether pioglitazone (PPARγ agonist) would prevent mild cognitive impairment (MCI) in asymptomatic people at genetic risk for AD (Burns et al., 2019). Here, PPARG is linked to Alzheimer disease.